Results 81 to 90 of about 25,748 (208)

Eruptive Xanthomas in a Patient With Severe Dyslipidemia

JEADV Clinical Practice, EarlyView.
Michał Niedźwiedź, Julia Domurad‐Falenta, Małgorzata Skibińska, Katarzyna Poznańska‐Kurowska   +3 more
wiley   +1 more source

Simvastatin Restores Cisplatin Sensitivity by Suppressing the Caveolin‐1‐Mediated PI3K/AKT Signaling Pathway in Cisplatin‐Resistant Cervical Cancer Cells

The FASEB Journal, Volume 40, Issue 9, 15 May 2026.
Simvastatin synergizes with cisplatin in cisplatin‐resistant cervical cancer cells through suppression of the caveolin‐1‐mediated PI3K/AKT signaling axis. ABSTRACT Cervical cancer treatment is often hindered by the emergence of cisplatin (DDP) resistance. Increasing evidence has indicated that statins possess anti‐tumor and chemosensitization potential
Yujia Zhou, Hejing Liu, Shuangjia Pan, Luyi Ruan, Jiayi Ruan, Jiaru Chen, Huihui Ji, Xueqiong Zhu   +7 more
wiley   +1 more source

Fenofibrate protects endothelial cells against the harmful effects of TNF-alpha

SA Heart Journal, 2017
Introduction: Fenofibrate exerts pleiotropic effects on endothelial cells (ECs) by, amongst others, increasing nitric oxide (NO) production. We aimed to investigate fenofi brate’s putative beneficial actions in healthy or TNF-alpha-induced dysfunctional ...
Westcott, Corli , Genis, Amanda , Mthethwa, Mashudu , Graham, Roxanne, van Vuuren, Derick , Huisamen, Barbara , Strijdom, Hans   +6 more
doaj   +1 more source

Liver Fibrosis: Molecular Pathogenesis and Therapeutic Interventions

MedComm, Volume 7, Issue 5, May 2026.
We systematically summarized the etiologies, diagnostic approaches, and pathogenic mechanisms of liver fibrosis. Also, the therapeutic interventions for liver fibrosis were systematically classified into two main categories: etiological treatment and mechanism‐based antifibrotic therapies.
Jiaorong Qu, Wenqing Qin, Minghang Dong, Zhi Ma, Si Li, Runping Liu, Ranyun Chen, Changmeng Li, Xiaojiaoyang Li   +8 more
wiley   +1 more source

The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice [PDF]

, 2018
journal ...
Araki Masaya, Han Song-iee, IWASAKI Hitoshi, Kumagai Kae, MATSUZAKA Takashi, Mizunoe Yuhei, NAKAGAWA Yoshimi, Ohno Hiroshi, Oishi Asayo, SEKIYA Motohiro, SHIMANO Hitoshi, Wang Yunong   +11 more
core   +2 more sources

GPIHBP1 Autoantibody‐Related Hypertriglyceridemia in Children: A Report of Two Cases and a Review of Pediatric Cases From the Literature

Molecular Genetics &Genomic Medicine, Volume 14, Issue 5, May 2026.
We report two young children with severe hypertriglyceridemia lacking monogenic causes. Both were ANA‐positive, with confirmed anti‐GPIHBP1 antibodies. Immunosuppressive therapy (hydroxychloroquine ± prednisolone) effectively reduced triglycerides. GPIHBP1 autoantibody‐related hypertriglyceridemia is an important pediatric cause, requiring accurate ...
Rai‐Hseng Hsu, Wuh‐Liang Hwu, Feng‐Jung Yang, Ni‐Chung Lee, Yin‐Hsiu Chien   +4 more
wiley   +1 more source

ROS accumulation and IGF-IR inhibition contribute to fenofibrate/PPARα -mediated inhibition of Glioma cell motility in vitro

Molecular Cancer, 2010
Background Glioblastomas are characterized by rapid cell growth, aggressive CNS infiltration, and are resistant to all known anticancer regimens. Recent studies indicate that fibrates and statins possess anticancer potential.
Del Valle Luis, Wybieralska Ewa, Grabacka Maja, Wilk Anna, Urbanska Katarzyna, Drukala Justyna, Madeja Zbigniew, Reiss Krzysztof   +7 more
doaj   +1 more source

EFFECT OF MILLING PROCESS ON PHYSICAL CHARACTERISTICS OF FENOFIBRATE [PDF]

, 2017
Particle size is ones of the most important characteristic of active drug substance that affects solubility and bioavailability. Fenofibrate, as a class II drug based on biopharmaceutical classification system, which has poor aqueous solubility has been ...
Avanti, Christina, Pradana, Aditya Trias, Susetyo, Amelia   +2 more
core  

Fenofibrate-promoted hepatomegaly and liver regeneration are PPARα-dependent and partially related to the YAP pathway

Acta Pharmaceutica Sinica B
Fenofibrate, a peroxisome proliferator-activated receptor α (PPARα) agonist, is widely prescribed for hyperlipidemia management. Recent studies also showed that it has therapeutic potential in various liver diseases.
Shicheng Fan, Yue Gao, Pengfei Zhao, Guomin Xie, Yanying Zhou, Xiao Yang, Xuan Li, Shuaishuai Zhang, Frank J. Gonzalez, Aijuan Qu, Min Huang, Huichang Bi   +11 more
doaj   +1 more source

Emerging Role of Ferroptosis in Diabetes and Associated Complications: When Metabolic Dysregulation Meets Cell Death

Cell Proliferation, Volume 59, Issue 5, May 2026.
This study identifies ferroptosis as a key driver of diabetes and its complications via iron metabolism and lipid peroxidation, elucidates organelle interactions underlying cell vulnerability, and provides insights for targeted therapies against metabolic disorders.
Zheng Wang, Ying Zhang, Yue Xu, Mengyuan Yang, Yuan Wei, Yuan Li, Tongyue Yang, Xu Wang, Chaona Yang, Qi Feng, Guolan Xing   +10 more
wiley   +1 more source